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Ca
oth
MaOBJECTIVES This study sought to determine the contemporary clinical characteristics and outcomes of patients with
ST-segment elevation myocardial infarction (STEMI) and previous coronary artery bypass graft (CABG), including those
with a saphenous vein graft culprit lesion.
BACKGROUND The outcome of STEMI patients with previous CABG is reported to be inferior to those without previous
CABG, but limited data is available from the primary percutaneous coronary intervention era.
METHODS Data was extracted from a large, regional STEMI system’s prospective database, which contained 3,542
unique STEMI episodes from March 4, 2003 through April 22, 2012.
RESULTS Previous CABG was present in 249 patients (7%). Despite higher comorbidity, patients with versus those
without previous CABG had similar in-hospital (4.8% vs. 5.2%; p ¼ 0.82) and 1-year (10.8% vs. 9.1%; p ¼ 0.36)
mortality, but 5-year (24.9% vs. 14.2%; p < 0.001) mortality was higher. Patients with previous CABG have similar
door-to-balloon times. The culprit vessel was the saphenous vein graft in 84 patients (34%), a native vessel in 104
(42%), with no clear culprit in 59 (24%). The left internal mammary artery graft was not a culprit in any patient. Mortality
at 30 days (8.3% vs. 3.9% vs. 1.7%, p ¼ 0.19) and 1 year (14.3% vs. 9.0% vs. 6.8%; p ¼ 0.35) was higher (but not
statistically) with a saphenous vein graft culprit and was equivalent at 5 years (25.0% vs. 26.0% vs. 20.3%; p ¼ 0.71).
CONCLUSIONS Patients with previous CABG treated in a regional STEMI system have similar outcomes as patients
without previous CABG, although 5-year mortality is higher. The most common culprit location was a native vessel
(42%). Outcomes have improved signiﬁcantly compared with historical reports. (J Am Coll Cardiol Intv 2014;7:981–7)
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982Patients with previous CABG compose a
small percentage of all patients who present
with STEMI, and this subset of patients
has not been well characterized. In STEMI
patients with previous CABG undergoing
primary balloon angioplasty, the in-hospital
and 6-month mortality was increased com-
pared with that of patients without previous
CABG, especially when the culprit was a
saphenous vein graft (SVG) (6). Bare-metal
stent placement was subsequently demon-
strated to be superior to balloon angioplasty,
with respect to major adverse cardiac out-
comes (MACE), in the treatment of obstruc-
ted venous bypass grafts (7). Drug-eluting
stents were then shown to be superior tobare-metal stents in the treatment of SVG lesions (8).
Previous reports, including post-hoc analyses of ran-
domized clinical trials, have described lower rates of
primary PCI and/or inferior clinical outcomes after
STEMI in patients with previous CABG, especially
those with a SVG culprit lesion (9–13).
Based on available data, STEMI in the setting of
previous CABG or STEMI with the presence of culprit
lesion in a bypass graft may confer an increased rate
of morbidity and mortality. However, the literature
remains limited and is confounded by lower rates
of intervention among those with previous CABG.
In addition, signiﬁcant advancements have been
made in stent design, adjunctive pharmacology, and
development of regional STEMI systems. Therefore,
our goal was to determine the contemporary outcome
of patients with previous CABG who presented with
STEMI.
METHODS
The Minneapolis Heart Institute at Abbott North-
western Hospital in Minneapolis, Minnesota, is a ter-
tiary cardiovascular center with established referral
relationships with community hospitals throughout
Minnesota and western Wisconsin. In 2003, a regional
system for the management of STEMI, the “Level 1”MI
program, was initiated with a standardized protocol
for transfer of STEMI patients for primary or pharma-
coinvasive PCI from 31 community hospitals up to 210
miles (338 km) from the PCI center. The detailed
design and results of the Level 1 MI program have been
previously reported (14–16). All patients with STEMI or
new left bundle branch block within 24 h of symptom
onset are included in the Level 1 MI program. No
patients were excluded from the protocol unless a
cardiology physician felt that reperfusion therapy was
inappropriate (e.g., advanced dementia or widelymetastatic cancer). All patients, including those with
advanced age, out-of-hospital cardiac arrest, and
cardiogenic shock were included in the data analysis
(15). All patients included in the database received
emergent coronary angiography unless they expired
during transport to the cardiac catheterization labo-
ratory. Institutional review board approval was ob-
tained, including waiver of consent for in-hospital
data collection, data analysis, and follow-up up to
5 years.
Using a comprehensive prospective database
from 3,542 consecutive patients treated as part
of the Level 1 MI regional STEMI program from
March 4, 2003 through April 22, 2012, we examined
demographic information; cardiovascular risk factors;
cardiac medications at presentation; clinical condi-
tion at presentation; time to treatment; angiographic
ﬁndings; cardiac biomarkers during hospitalization;
and short- and long-term outcomes, which included
mortality (in-hospital, 30-day, 1-year, and 5-year) and
30-day cardiac readmission, reinfarction or recurrent
ischemia, stroke, or combined MACE.
Patients with previous CABG were further stratiﬁed
to 3 groups by culprit lesion based on ECG and
angiographic ﬁndings: 1) SVG culprit; 2) native vessel
culprit; or 3) no clear culprit. Patients with no culprit
artery identiﬁed were stratiﬁed by the presence or
absence of positive cardiac biomarkers (Figure 1).
Descriptive statistics were reported as mean  SD;
categorical variables as number and percentage
with characteristic. Where continuous variables had
skewed distributions (length of stay, door-to-balloon
times), median (25th and 75th percentiles) were re-
ported. Continuous variables were assessed using
analysis of variance or Student t-test, and categorical
variables using chi-square or Fisher exact tests.
Kruskal-Wallis rank tests were used to compare
continuous variables with skewed distribution. A
p value of <0.05 was considered statistically signiﬁ-
cant and p values are 2-sided whenever possible. All
analyses were performed with Stata (version 11.2,
StataCorp, College Station, Texas).
RESULTS
Of 3,542 consecutive patients with STEMI, 249 (7%)
had a history of previous CABG. These patients were
older, more likely male, with increased prevalence of
previous MI, PCI, and some cardiovascular risk factors,
including diabetes mellitus, but with lower current
smoking rates (Table 1). The incidence of anterior MI
was higher in patients without previous CABG (35.5%
vs. 23.6%; p < 0.001), which is likely due to the pres-
ence of left internal mammary artery grafts. There was
FIGURE 1 Study Flow Diagram
Stratiﬁcation of patients from the Level 1 MI project database for the current study. The absolute number and percentage are included for each
group. CABG ¼ coronary artery bypass graft; Neg ¼ negative; PCI ¼ percutaneous coronary intervention; Pos ¼ positive; Pts ¼ patients;
STEMI ¼ ST-segment elevation myocardial infarction; SVG ¼ saphenous vein graft.
TABLE 1 Characteristics of All Patients Split by History of Previous CABG
Previous CABG
(n ¼ 249)
No Previous CABG
(n ¼ 3,303) p Value
Age, yrs 69.4  12.0 62.1  14.3 <0.001
Male 203 (81.5) 2,325 (70.6) <0.001
Hypertension 207 (83.1) 1,859 (56.7) <0.001
Dyslipidemia 216 (87.5) 1,679 (52.4) <0.001
Diabetes 88 (35.5) 519 (15.8) <0.001
History of CAD 249 (100) 810 (24.6) <0.001
Family history of CAD 98 (42.1) 1354 (43.1) 0.76
History of smoking 146 (59.4) 1,996 (61.0) 0.60
Current smoker* 47 (32.2) 1,233 (61.8) <0.001
Previous MI 161 (66.0) 533 (16.2) <0.001
Previous PCI 136 (55.5) 593 (18.0) <0.001
History of stroke 10 (4.1) 80 (2.5) 0.13
Cardiogenic shock pre-PCI 20 (8.0) 279 (8.5) 0.81
Cardiac arrest pre-PCI 15 (6.0) 296 (9.0) 0.11
Anterior MI 57 (23.6) 1,155 (35.5) <0.001
Killip class 1.00
1 217 (87.2) 2,868 (87.2)
2–4 32 (12.9) 423 (12.9)
Admission medications† 142 1,839
Aspirin 111 (78.2) 667 (36.3) <0.001
Beta-blocker 98 (69.0) 499 (27.2) <0.001
ACE-inhibitor 70 (49.3) 399 (21.7) <0.001
Statin 95 (66.9) 517 (28.1) <0.001
Antiplatelet 29 (20.4) 133 (7.2) <0.001
Values are mean  SD, n (%), or n. *Percentage of current smokers based on the number of
patients with a positive history of smoking. †Admission medications only available for patients
presenting after April 1, 2009.
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass graft; CAD ¼ coronary
artery disease; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention
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983no difference in pre-PCI cardiogenic shock, out of
hospital cardiac arrest, or Killip class at the time
of presentation. Use of cardiac medications, includ-
ing aspirin, beta-blockers, angiotensin-converting
enzyme inhibitors, and 3-hydroxy-3-methylglutaryl
coenzyme A reductase inhibitors (statins), was higher
among patients with previous CABG (Table 1).
Time to intervention was similar in patients with
and without previous CABG (Table 2). Patients
without previous CABG were more likely to demon-
strate decreased ﬂow (TIMI [Thrombolysis In Myo-
cardial Infarction] ﬂow grade 0 or 1) in the culprit
artery, but they were noted to have equivalent post-
procedural ﬂow. Primary PCI was performed on
67.5% of the patients in the previous CABG group, as
compared to 79.8% of those without previous CABG
(p < 0.001). The likelihood of ﬁnding “no clear
culprit” was higher in patients with previous CABG
(23.7% vs. 15.4%, p ¼ 0.001).
Among patients with previous CABG versus those
without, mean peak creatine kinase-myocardial band
level was signiﬁcantly lower (38 vs. 69, p < 0.001),
and the left ventricular ejection fraction measured
during hospitalization was lower (45.2% vs. 47.3%,
p ¼ 0.02), likely reﬂecting the higher prevalence of
previous MI. There was no signiﬁcant difference in
median length of stay or in-hospital death (Table 2).
MACE at 30 days (including stroke, recurrent infarc-
tion, recurrent ischemia, or death) and rates of hos-
pital readmission at 30 days for cardiac causes were
equivalent in the 2 groups. At 1 year, no signiﬁcant
TABLE 2 Angiographic and Clinical Outcomes of All Patients Split by
History of Previous CABG
Previous CABG
(n ¼ 249)
No Previous CABG
(n ¼ 3,303) p Value
No clear culprit artery 59 (23.7) 507 (15.7) 0.001
TIMI ﬂow grade pre-PCI 0.029
0/1 96 (39.8) 1,519 (47.1)
2/3 145 (60.2) 1,707 (52.9)
TIMI ﬂow grade post-PCI 0.19
0/1 8 (3.3) 66 (2.1)
2/3 233 (96.7) 3,158 (98.0)
Peak CK 397 (159–1,103) 726 (241–1,664) <0.001
Peak CK-MB 38 (9–105) 69 (19–170) <0.001
Ejection fraction, % 45.2  14.4 47.3  13.3 0.021
Primary PCI performed 168 (67.5) 2,628 (79.8) <0.001
Length of stay, days 3 (2–4) 3 (2–4) 0.61
Door to balloon,* min 98 (76–122) 95 (74–125) 0.39
Death in-hospital 12 (4.8) 170 (5.2) 0.82
Outcomes at 30 days
Cardiac readmission†‡ 4 (1.7) 72 (2.3) 0.82
Stroke†‡ 2 (0.8) 26 (0.8) 1.00
Reinfarction/reischemia†‡ 3 (1.3) 41 (1.3) 1.00
Death 12 (4.8) 194 (5.9) 0.49
MACE 17 (6.8) 242 (7.4) 0.76
Outcomes at 1 year
Cardiac readmission‡ 21 (8.9) 205 (6.6) 0.17
Stroke†‡ 5 (2.1) 34 (1.1) 0.19
Reinfarction/reischemia‡ 10 (4.2) 87 (2.8) 0.20
Death 27 (10.8) 301 (9.1) 0.36
MACE 39 (15.7) 403 (12.2) 0.12
Death at 5 years 62 (24.9) 466 (14.2) <0.001
Values are n (%), median (interquartile range), or mean  SD. *Door-to-balloon time represents
the total time from presentation at a referral emergency department or hospital to the ﬁrst device
at the PCI hospital, including time for transport to Abbott Northwestern Hospital. Patients who
expired prior to coronary angiography are included in the database for calculation of mortality,
but they are not assigned a door to balloon time. †Fisher exact test used to assess statistical
signiﬁcance. ‡Percentage based on those patients alive at discharge.
CK ¼ creatine kinase; CK-MB ¼ creatine kinase-myocardial band; MACE ¼major adverse cardiac
events (death, stroke, recurrent ischemia, or infarction); TIMI ¼ Thrombolysis In Myocardial
Infarction.
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there was an increased rate of death at 5 years among
those with CABG (24.9% vs. 14.2%, p < 0.001).
RESULTS BASED ON CULPRIT LESION. Patients with
CABG as stratiﬁed by culprit lesion (SVG, native vessel,
no culprit), are compared in Table 3. Among patients
with previous CABG, the culprit lesion was identiﬁed
as a SVG in 84 patients (34%) and as a native vessel
in 104 (42%). No clear culprit was identiﬁed in 59 pa-
tients (24%) and 2 patients (1%) were found to have
native and SVG coculprit lesions. Among patients with
no clear culprit artery on coronary angiography, 19 of
59 (32.2%) had elevated biomarkers. The 2 patients
with multiple culprits were excluded from further
analysis. The left internal mammary artery was not
identiﬁed as the culprit artery in any case.Patients with a native vessel culprit were less likely
to report a history of smoking but were more likely to
be current smokers and had lower rates of treatment
with beta-blockers or angiotensin-converting enzyme
inhibitors at the time of admission. Patients with a
SVG culprit lesion, as compared to those with a native
vessel culprit, had increased rates of pre-PCI shock
(14.3% vs. 4.8%, p ¼ 0.038). Patients without clear
culprit lesions were more likely to present with
anterior MI by ECG.
The angiographic and clinical outcomes of the
patients with CABG, as stratiﬁed by culprit lesions,
are displayed in Table 4. Door-to-balloon times are
comparable in the 3 groups. As expected, patients
without a clear culprit had normal TIMI ﬂow and did
not undergo PCI. In contrast with previous reports,
there was no difference in the rate of intervention
between SVG culprit (85.7%) and native vessel culprit
(91.4%) groups (p ¼ 0.22). Mortality in patients with
SVG culprit was numerically, but not statistically,
different from those with native vessel or no culprit
(in-hospital mortality: 8.3% vs. 3.9% vs. 1.7%, p¼ 0.19;
1-year mortality: 14.3% vs. 9.6% vs. 6.8%, p ¼ 0.35).
There were no differences in length of stay, read-
mission for cardiac causes at 30 days, or MACE at
30 days.
DISCUSSION
This report represents the largest cohort of patients
with previous CABG undergoing primary PCI for
STEMI. Notably, 7% of the current study population
had previous CABG, which represents an increased
prevalence when compared with previous reports
(2.2% to 5.3%). In patients with previous CABG, the
culprit artery was more frequently a native vessel
(42%) than a SVG (34%), and these patients had a
greater burden of medical comorbidities. The left
internal mammary artery graft was never identiﬁed
as a culprit vessel, which may explain the lower
incidence of anterior MI and is a further testament
to the durability of this graft. In this prospectively
collected registry involving a large number of pa-
tients, we did not identify increased rates of mor-
tality at 30 days or 1 year after STEMI in those
with previous CABG. This observation contrasts with
previous reports and may represent the inﬂuence of
the regional STEMI system using a standardized
protocol with aggressive evidence-based therapy,
including timely PCI. Mortality in the subgroup of
patients with a SVG culprit vessel was numerically,
but not statistically, higher when compared with that
of patients with a native vessel culprit or no clear
culprit.
TABLE 3 Characteristics of Patients With Previous CABG Split by
Culprit Lesion
Culprit SVG
(n ¼ 84)
Native Culprit
(n ¼ 104)
No Culprit
(n ¼ 59) p Value
Age, yrs 69.2  11.7 69.4  12.0 69.1  12.5 0.99
Male 70 (83.3) 86 (82.7) 46 (78.0) 0.68
Hypertension 71 (84.5) 80 (76.9) 54 (91.5) 0.052
Dyslipidemia 71 (84.5) 93 (90.3) 51 (87.9) 0.49
Diabetes 30 (35.7) 32 (31.1) 25 (42.4) 0.35
Family history of CAD 32 (41.0) 38 (38.8) 27 (49.1) 0.45
History of smoking 53 (63.1)‡ 49 (48.0)‡ 43 (74.1)‡ 0.004
Current smoker* 17 (32.1) 18 (36.7) 11 (25.6) 0.52
Previous MI 52 (62.7) 69 (67.7) 40 (70.2) 0.62
Previous PCI 44 (52.4) 57 (56.4) 34 (58.6) 0.74
History of stroke† 3 (3.6) 4 (3.9) 3 (5.2) 0.84
Cardiogenic shock pre-PCI 12 (14.3)‡ 5 (4.8)‡ 3 (5.1)‡ 0.038
Cardiac arrest† pre-PCI 4 (4.8) 7 (6.7) 4 (6.8) 0.84
Anterior MI 13 (15.7)‡ 23 (22.6)‡ 21 (38.2)‡ 0.009
Killip class 0.17
0/1 69 (82.1) 95 (91.4) 51 (86.4)
2/4 15 (17.9) 9 (8.7) 8 (13.6)
Admission medications§ 43 69 30
Aspirin 36 (83.7) 49 (71.0) 26 (86.7) 0.13
Beta-blocker 33 (76.7)‡ 40 (58.0)‡ 25 (83.3)‡ 0.018
ACE inhibitor 21 (48.8)‡ 28 (40.6)‡ 21 (70.0)‡ 0.027
Statin 30 (69.8) 41 (59.4) 24 (80.0) 0.12
Antiplatelet 8 (18.6) 13 (18.8) 8 (26.7) 0.63
Values are mean  SD, n (%), or n. *Percentage of current smokers based on the number
of patients with a positive history of smoking. †Fisher exact test used to assess statistical
signiﬁcance. ‡Superscripts that are the same do not signiﬁcantly differ (p > 0.05). §Admission
medications only available for patients presenting after April 1, 2009.
SVG ¼ saphenous vein graft, other abbreviations as in Table 1.
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985Previous studies have suggested increased mor-
tality after STEMI in those with previous CABG,
especially among those with a SVG culprit vessel, and
this greater mortality may reﬂect a combination of
inadequate adjunctive medical therapy, older stent
technology, and lower rates of reperfusion or PCI
among those with previous CABG. In the report of
Stone et al. (6) from the PAMI-2 (Second Primary
Angioplasty in Myocardial Infarction Study) (1993 to
1995), a signiﬁcantly lower rate of balloon angioplasty
and post-procedural TIMI ﬂow was achieved in 58
patients with previous CABG. In-hospital death was
increased among those with previous CABG and those
with SVG culprit lesions. Notably, coronary stenting
and dual antiplatelet medications were not standard
at the time. Similarly, Brodie et al. (17) report inferior
short- and long-term outcomes of 57 patients with
SVG culprit lesions treated with percutaneous trans-
luminal coronary angioplasty and early coronary
stents from 1984 to 2003. As was the case in the
previous study, signiﬁcantly fewer patients with SVG
culprit lesions were noted to have post-procedural
TIMI ﬂow grade 3. These patients were reported to
have signiﬁcantly increased in-hospital and long-
term mortality when compared with all patients
with a native vessel culprit (including 50 patients
with prior bypass).
Only 2 contemporary reports have been published
involving randomized clinical trials of patients with
previous CABG and STEMI treated with PCI. The ﬁrst
is a post-hoc analysis of the APEX-AMI (Assessment of
Pexelizumab in Acute Myocardial Infarction) trial in
which 128 study participants (2.2%) had undergone
previous CABG (10). In patients with previous CABG,
successful reperfusion was less likely, and 90-day
mortality was signiﬁcantly greater. The 90-day mor-
tality rate among patients with a SVG infarct-related
artery (IRA) (19.0%) was signiﬁcantly increased after
multivariate analysis (hazard ratio: 3.3) when
compared with native IRA in patients with previous
CABG (5.7%, p ¼ 0.031) or a native IRA in patients
without previous bypass (4.6%, p < 0.01). The out-
comes of patients with a native IRA, regardless of
bypass status, are similar to our experience. Among
those with a SVG culprit, we report lower rates of
morality, despite an excess of shock on presentation,
and statistically noninferior clinical outcomes. The
excess mortality reported from APEX-AMI may
represent type I error given the limited sample size or
may be related to the decreased rates of post-
procedural TIMI grade 3 ﬂow in infarct-related
bypass grafts due to lower rates of primary PCI. The
second contemporary report is a post-hoc analysis of
the HORIZONS-AMI (Harmonizing Outcomes WithRevascularization and Stents in Acute Myocardial
Infarction) trial, which found increased MACE at
3 years among 105 patients with previous bypass,
regardless of IRA (6). This result was driven by
signiﬁcantly higher rates of target vessel revascular-
ization and stroke. A trend toward increased mortal-
ity did not reach statistical signiﬁcance. These
ﬁndings are confounded by longer door-to-balloon
times, lower rates of referral to primary PCI, and
inferior post-PCI TIMI ﬂow grades among those with
previous CABG. After multivariate analysis, neither
previous CABG nor SVG culprit was associated with
increased 3-year mortality or MACE.
In our study, the rate of primary PCI among
patients with previous CABG was lower, albeit to a
smaller degree, when patients with no clear culprit
artery are censored (88.4% vs. 95.4%, p < 0.001).
There were, however, no signiﬁcant differences in
post-PCI TIMI ﬂow grades between the 2 groups, as
was described in previous studies, suggesting that
clinical outcomes may be equalized if comparable
reperfusion is achieved with current therapies.
TABLE 4 Angiographic and Clinical Outcomes of Patients With Previous CABG Split
by Culprit Lesion
Culprit SVG
(n ¼ 84)
Native Culprit
(n ¼ 104)
No Culprit
(n ¼ 59) p Value
TIMI ﬂow grade pre-PCI* <0.001
0/1 47 (56.6)† 49 (48.0)† 0 (0)†
2/3, (%) 36 (43.4) 53 (52.0) 54 (100)
TIMI ﬂow grade post-PCI* 0.061
0/1 6 (7.2) 2 (2.0) 0 (0)
2/3 77 (92.8) 100 (98.0) 54 (100)
Peak CK 571 (216, 1,480)† 573 (260, 1,337)† 139 (79, 275)† <0.001
Peak CK-MB 46 (20, 113)† 65 (18, 139)† 7 (7, 15)† <0.001
Ejection fraction, % 44.8  13.7 44.8  14.9 46.8  14.9 0.65
Primary PCI performed 72 (85.7)† 95 (91.4)† 0 (0)† <0.001
Length of stay, days 3 (2, 5) 3 (2, 4) 2 (1, 5) 0.23
Door to balloon,‡ min 95 (75, 119) 98 (74, 119) 106 (83, 129) 0.40
Death in-hospital* 7 (8.3) 4 (3.9) 1 (1.7) 0.19
Outcomes at 30 days
Cardiac readmission*§ 1 (1.3) 3 (3.0) 1 (1.7) 0.85
Stroke*§ 1 (1.3) 0 (0) 1 (1.7) 0.33
Reinfarction/reischemia*§ 2 (2.6) 1 (1.0) 0 (0) 0.61
Death* 7 (8.3) 4 (3.9) 1 (1.7) 0.19
MACE* 10 (11.9) 5 (4.8) 2 (3.4) 0.11
Outcomes at 1 year
Cardiac readmission*§ 10 (13.0) 9 (9.0) 2 (3.5) 0.18
Stroke*§ 2 (2.6) 2 (2.0) 1 (1.7) 1.00
Reinfarction/reischemia*§ 3 (3.9) 7 (7.0) 0 (0) 0.099
Death* 12 (14.3) 10 (9.6) 4 (6.8) 0.35
MACE* 8 (10.4) 14 (14.0) 4 (6.9) 0.40
Death at 5 years* 21 (25.0) 27 (26.0) 12 (20.3) 0.71
Values are n (%), median (IQR), or mean  SD. *Fisher exact test used to assess statistical signiﬁcance.
†Superscripts that are the same do not statistically differ. ‡Door-to-balloon time represents the total time from
presentation at a referral emergency department or hospital to the ﬁrst device at the PCI hospital, including time
for transport to Abbott Northwestern Hospital. Patients who expired prior to coronary angiography are included
in the database for calculation of mortality, but they are not assigned a door-to-balloon time. §Percentage based
on those patients alive at discharge.
Abbreviations as in Tables 1 and 2.
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986Excess 5-year mortality may merely reﬂect other risk
factors including greater age, lower left ventricular
ejection fraction, and more extensive coronary artery
disease of the CABG group.
The strengths of this study include a large sample
size: the 249 patients with previous CABG represent
the largest prospective series to date. Although this
cohort is nonrandomized and drawn from a prospec-
tive registry, the design allows for provision of
evidence-based therapy throughout the study period
(2003 to 2012) and ensures that treatment reﬂects
current clinical practice. The Minneapolis Heart In-
stitute’s Level 1 MI program is designed to evolve in
parallel with changes in contemporary standards of
care, including preferential use of newer-generation
drug-eluting stents and bivalirudin during coro-
nary intervention, which may improve outcomes in
patients with advanced disease or multiple medical
comorbidities. Perhaps more importantly, the time toreperfusion (door-to-balloon time) and adjunctive
medical therapy are similar because standardized
protocols have been used in the regional STEMI sys-
tem, a strategy that has demonstrated efﬁcacy in
improving the clinical outcomes of women and
elderly patients (18). In addition to interventional
cardiologists, we believe that this data has broad
applicability to the emergency medicine, internal
medicine, or general cardiology physicians treating a
patient with previous CABG who presents with acute
chest pain and ST-segment elevation.
When patients with previous CABG are stratiﬁed
by culprit artery, several interesting trends emerge.
There is an increased prevalence of cardiogenic shock
at hospital admission among those with a SVG culprit
artery. Interestingly, when compared with patients
with a native vessel culprit, there are no corre-
sponding differences in baseline ejection fraction,
rates of reperfusion, post-PCI ﬂow, infarct size, or
length of stay. There is also a trend toward increased
mortality at 30 days and 1 year among patients with
an SVG culprit that did not reach clinical signiﬁcance.
As noted, Welsh et al. (9) reported a similar ﬁnding in
their analysis of the APEX-AMI data. The relatively
small numbers of patients, per culprit artery, limit
the statistical power with respect to subgroup anal-
ysis, and it is possible that this trend toward
increased mortality is real and reﬂects the increased
rates of shock on arrival. In patients with previous
CABG and no clear culprit identiﬁed on angiography,
approximately one-third were noted to have positive
cardiac enzymes. The remaining two-thirds included
patients with left bundle branch block, prior MI,
and other ECG mimics, characteristics similar to
those described in a previous report (2). Whereas one
must maintain a high index of suspicion for acute
ischemia patients with previous bypass, the absence
of cardiac enzyme elevation in 16% of patients with
previous CABG highlights the value of obtaining an
old ECG for comparison and, potentially, reviewing
the case with a consulting cardiologist prior to cath-
eterization lab activation. The removal of a “new”
left bundle branch block as an ECG criterion for
catheterization lab activation in the most recent
American College of Cardiology Foundation/Amer-
ican Heart Association guidelines for the manage-
ment of STEMI may also decrease the risk of false
activation in patients with previous CABG. Never-
theless, one-third of patients with previous CABG
and no clear culprit had elevated biomarkers and
the 30-day, 1-year, and 5-year mortality was similar
to patients with a SVG or native vessel culprit,
highlighting the signiﬁcant comorbid illness in this
population.
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987STUDY LIMITATIONS. Although prospective, this
study is nonrandomized; however, it is unlikely a
randomized trial will ever be conducted. The regional
STEMI program database captures only patients re-
ferred for urgent angiography and therefore possibly
includes a referral bias. It remains a large sample, and
our previous reports suggest very low rates of eligible
but untreated patients. Finally, the power to analyze
differences in clinical outcome may be limited by the
small sample size available.
CONCLUSIONS
In a large, prospective STEMI database, there was no
excess 1-year mortality, MACE, or rehospitalization
among patients with previous CABG versus patientswithout previous bypass surgery. Mortality at 5 years
is increased among patients with previous bypass.
Although adverse clinical outcomes, including death,
were numerically increased in those with a SVG
culprit, this ﬁnding did not reach statistical signiﬁ-
cance. This study demonstrates that contemporary
1-year clinical outcomes of STEMI patients with pre-
vious CABG are equivalent to those of an unselected
STEMI population with use of a standardized protocol
and early reperfusion with primary PCI.
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